Leland Stanford Junior University

University of Michigan

Oncomed Pharmaceuticals, Inc.

Piero D Dalerba

Irving L Weissman

Michael F Clarke

Jens-Peter Volkmer

Stephen Willingham

Doris Po Yi Ho

Kelly Marie McKenna

Stephen R Quake

Maximilian Diehn

Jianbin Wang

Huiping Liu

Anne A Leyrat

Tomer Kalisky

Austin L Gurney

Scott J Dylla

Tim Hoey

Xinhao Wang

Neethan A Lobo

Mark Prince

Grace Chen

Michael Rothenberg

Anne Leyrat

Maximillian Diehn

Methods are provided for targeting cells for depletion, including, without limitation, cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS and BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

Treatment of cancer with dual targeting of CD47 and EGFR

Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.

Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells.

Methods and systems for analysis of single cells

Single cell gene expression for diagnosis, prognosis and identification of drug targets

The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells.

Compositions and methods for treating and diagnosing cancer

Growing community of inventors

Palo Alto, CA, United States of America

Piero D Dalerba